Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
2seventy bio
Pharma
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
The two companies attributed the termination to enrollment challenges as the multiple myeloma treatment landscape shifts to more powerful treatments.
Angus Liu
Sep 25, 2024 10:52am
BMS' Abecma wins earlier myeloma nod with updated boxed warning
Apr 5, 2024 11:46am
FDA sets date for high-profile CAR-T advisory committee meeting
Feb 2, 2024 1:31pm
2seventy bio plots Abecma turnaround amid strategic pivot
Jan 30, 2024 11:25am
FDA calls for adcomm on BMS's Abecma in earlier treatment line
Nov 20, 2023 11:30am
2seventy suffers CAR-T commercialization pitfalls with Abecma
Nov 15, 2023 11:10am
